These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 20050100)

  • 41. The effects of nebivolol on fibrinolytic parameters in mild and moderate hypertensive patients.
    Tarighi B; Kurum T; Demir M; Azcan SN
    Can J Cardiol; 2007 Jun; 23(8):651-5. PubMed ID: 17593991
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: the YESTONO study.
    Schmidt AC; Graf C; Brixius K; Scholze J
    Clin Drug Investig; 2007; 27(12):841-9. PubMed ID: 18020542
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Prospective follow-up of nebivolol in the treatment of arterial hypertension].
    Despotović N; Matić-Cvetković D; Ivanović B
    Srp Arh Celok Lek; 2012; 140(7-8):425-30. PubMed ID: 23092025
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Assessment of safety and antihypertensive efficacy of a cardioselective beta-blocker nebivolol in patients with hypertension and concomitant chronic obstructive bronchitis].
    Iakushin SS; Okorokov VG; Liferov RA; Fomina VA; Ivanova GO
    Kardiologiia; 2002; 42(11):36-9. PubMed ID: 12494034
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Antihypertensive efficacy and tolerability of nebivolol].
    Kirichenko AA; Mironova EV
    Kardiologiia; 2002; 42(12):35-7. PubMed ID: 12494015
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nebivolol reduces central blood pressure in stage I hypertensive patients: experimental single cohort study.
    Vaz-de-Melo RO; Giollo-Júnior LT; Martinelli DD; Moreno-Júnior H; Mota-Gomes MA; Cipullo JP; Yugar-Toledo JC; Vilela-Martin JF
    Sao Paulo Med J; 2014; 132(5):290-6. PubMed ID: 25054966
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Economic evaluation of nebivolol in the treatment of hypertension.
    Kaltwasser MT
    Am J Cardiovasc Drugs; 2005; 5(5):319-24. PubMed ID: 16156687
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sleep quality in patients with hypertension: additional negative effect of drug therapy.
    Yontar OC; Erdem A; Yilmaz MB
    Sleep Med; 2009 Dec; 10(10):1168; author reply 1168-9. PubMed ID: 19467925
    [No Abstract]   [Full Text] [Related]  

  • 49. New beta-blocker gets FDA approval.
    Traynor K
    Am J Health Syst Pharm; 2008 Feb; 65(3):190. PubMed ID: 18215997
    [No Abstract]   [Full Text] [Related]  

  • 50. Does nebivolol prevent contrast-induced nephropathy in humans?
    Günebakmaz O; Kaya MG; Koc F; Akpek M; Kasapkara A; Inanc MT; Yarlioglues M; Calapkorur B; Karadag Z; Oguzhan A
    Clin Cardiol; 2012 Apr; 35(4):250-4. PubMed ID: 22262230
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relation between clinical and therapeutic variables and quality of life in hypertension.
    Roca-Cusachs A; Dalfó A; Badia X; Arístegui I; Roset M
    J Hypertens; 2001 Oct; 19(10):1913-9. PubMed ID: 11593114
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Treatment of hypertension and QOL assessment].
    Mikami H
    Nihon Rinsho; 2000 Feb; 58 Suppl 2():36-9. PubMed ID: 11028289
    [No Abstract]   [Full Text] [Related]  

  • 53. Investigation of nebivolol as a novel therapeutic agent for the treatment of Alzheimer's disease.
    Wang J; Wright HM; Vempati P; Li H; Wangsa J; Dzhuan A; Habbu K; Knable LA; Ho L; Pasinetti GM
    J Alzheimers Dis; 2013; 33(4):1147-56. PubMed ID: 23128558
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A retrospective study evaluating the tolerability and effectiveness of adjunctive antihypertensive drugs in patients with inadequate response to initial treatment.
    Ayyagari R; Xie J; Cheng D; Wu EQ; Huang XY; Chen S
    J Clin Hypertens (Greenwich); 2018 Jun; 20(6):1058-1066. PubMed ID: 29902367
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quality of life and efficacy of nebivolol in an open-label study in hypertensive patients. the QoLaN study.
    Hermans MP; De Coster O; Seidel L; Albert A; Van de Borne P
    Blood Press Suppl; 2009 Oct; 1():5-14. PubMed ID: 20050100
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life.
    Van Bortel LM; Breed JG; Joosten J; Kragten JA; Lustermans FA; Mooij JM
    J Cardiovasc Pharmacol; 1993 Jun; 21(6):856-62. PubMed ID: 7687708
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nationwide efficacy-safety study of nebivolol in mildly hypertensive patients.
    Cleophas TJ; Agrawal R; Lichtenthal A; Mäkel W; Fici F
    Am J Ther; 2006; 13(3):192-7. PubMed ID: 16772759
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW
    Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nebivolol: in the treatment of hypertension in the US.
    Baldwin CM; Keam SJ
    Am J Cardiovasc Drugs; 2009; 9(4):253-60. PubMed ID: 19655820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.